Attia E, Haiman C, Walsh B T, Flater S R
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, USA.
Am J Psychiatry. 1998 Apr;155(4):548-51. doi: 10.1176/ajp.155.4.548.
While pharmacological interventions are of established utility in bulimia nervosa, medications have no clear role in the treatment of anorexia nervosa. Because patients with anorexia nervosa frequently exhibit mood disturbances and symptoms of obsessive-compulsive disorder, the authors tested the utility of fluoxetine in the treatment of women participating in an inpatient program for anorexia nervosa.
The authors conducted a randomized, placebo-controlled, double-blind, 7-week study of fluoxetine at a target daily dose of 60 mg in 31 women with anorexia nervosa receiving treatment for their eating disorder on a clinical research unit. Body weight and measures of eating behavior and psychological state were obtained at baseline and at termination.
There were no significant differences in clinical outcome on any measure between patients receiving fluoxetine and patients receiving placebo.
Fluoxetine does not appear to add significant benefit to the inpatient treatment of anorexia nervosa.
虽然药物干预在神经性贪食症的治疗中已证实具有效用，但药物在神经性厌食症的治疗中尚无明确作用。由于神经性厌食症患者经常表现出情绪障碍和强迫症症状，作者测试了氟西汀在治疗参加神经性厌食症住院项目的女性中的效用。
作者对31名在临床研究单位接受饮食失调治疗的神经性厌食症女性进行了一项随机、安慰剂对照、双盲、为期7周的研究，氟西汀的目标日剂量为60毫克。在基线和结束时获取体重、饮食行为和心理状态的测量值。
接受氟西汀治疗的患者与接受安慰剂治疗的患者在任何测量指标上的临床结果均无显著差异。
氟西汀似乎并未给神经性厌食症的住院治疗带来显著益处。
